From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?
Since the outbreak of the COVID-19 pandemic in December 2019, the SARS-CoV-2 genome has undergone several mutations. The emergence of such variants has resulted in multiple pandemic waves, contributing to sustaining to date the number of infections, hospitalisations, and deaths despite the swift dev...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2022.2081847 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687109952077824 |
|---|---|
| author | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro |
| author_facet | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro |
| author_sort | Matteo Pavan |
| collection | DOAJ |
| description | Since the outbreak of the COVID-19 pandemic in December 2019, the SARS-CoV-2 genome has undergone several mutations. The emergence of such variants has resulted in multiple pandemic waves, contributing to sustaining to date the number of infections, hospitalisations, and deaths despite the swift development of vaccines, since most of these mutations are concentrated on the Spike protein, a viral surface glycoprotein that is the main target for most vaccines. A milestone in the fight against the COVID-19 pandemic has been represented by the development of Paxlovid, the first orally available drug against COVID-19, which acts on the Main Protease (Mpro). In this article, we analyse the structural features of both the Spike protein and the Mpro of the recently reported SARS-CoV-2 variant XE, as well the closely related XD and XF ones, discussing their impact on the efficacy of existing treatments against COVID-19 and on the development of future ones. |
| format | Article |
| id | doaj-art-688d4cd1fe3b4abfb29fdb91506ecf7b |
| institution | DOAJ |
| issn | 1475-6366 1475-6374 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Enzyme Inhibition and Medicinal Chemistry |
| spelling | doaj-art-688d4cd1fe3b4abfb29fdb91506ecf7b2025-08-20T03:22:26ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742022-12-013711704171410.1080/14756366.2022.2081847From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?Matteo Pavan0Davide Bassani1Mattia Sturlese2Stefano Moro3Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, ItalySince the outbreak of the COVID-19 pandemic in December 2019, the SARS-CoV-2 genome has undergone several mutations. The emergence of such variants has resulted in multiple pandemic waves, contributing to sustaining to date the number of infections, hospitalisations, and deaths despite the swift development of vaccines, since most of these mutations are concentrated on the Spike protein, a viral surface glycoprotein that is the main target for most vaccines. A milestone in the fight against the COVID-19 pandemic has been represented by the development of Paxlovid, the first orally available drug against COVID-19, which acts on the Main Protease (Mpro). In this article, we analyse the structural features of both the Spike protein and the Mpro of the recently reported SARS-CoV-2 variant XE, as well the closely related XD and XF ones, discussing their impact on the efficacy of existing treatments against COVID-19 and on the development of future ones.https://www.tandfonline.com/doi/10.1080/14756366.2022.2081847SARS-CoV-2COVID-19XE variantXD variantSpike proteinMpro |
| spellingShingle | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? Journal of Enzyme Inhibition and Medicinal Chemistry SARS-CoV-2 COVID-19 XE variant XD variant Spike protein Mpro |
| title | From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? |
| title_full | From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? |
| title_fullStr | From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? |
| title_full_unstemmed | From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? |
| title_short | From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? |
| title_sort | from the wuhan hu 1 strain to the xd and xe variants is targeting the sars cov 2 spike protein still a pharmaceutically relevant option against covid 19 |
| topic | SARS-CoV-2 COVID-19 XE variant XD variant Spike protein Mpro |
| url | https://www.tandfonline.com/doi/10.1080/14756366.2022.2081847 |
| work_keys_str_mv | AT matteopavan fromthewuhanhu1straintothexdandxevariantsistargetingthesarscov2spikeproteinstillapharmaceuticallyrelevantoptionagainstcovid19 AT davidebassani fromthewuhanhu1straintothexdandxevariantsistargetingthesarscov2spikeproteinstillapharmaceuticallyrelevantoptionagainstcovid19 AT mattiasturlese fromthewuhanhu1straintothexdandxevariantsistargetingthesarscov2spikeproteinstillapharmaceuticallyrelevantoptionagainstcovid19 AT stefanomoro fromthewuhanhu1straintothexdandxevariantsistargetingthesarscov2spikeproteinstillapharmaceuticallyrelevantoptionagainstcovid19 |